centene corp. - CNC
CNC
Close Chg Chg %
41.24 -0.08 -0.19%
Closed Market
41.16
-0.08 (0.19%)
Volume: 3.67M
Last Updated:
Dec 31, 2025, 3:59 PM EDT
Company Overview: centene corp. - CNC
CNC Key Data
| Open $41.11 | Day Range 41.05 - 41.79 |
| 52 Week Range 25.08 - 66.81 | Market Cap $20.23B |
| Shares Outstanding 491.52M | Public Float 479.15M |
| Beta 0.48 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$10.81 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.74M |
CNC Performance
| 1 Week | 1.58% | ||
| 1 Month | 7.33% | ||
| 3 Months | 6.33% | ||
| 1 Year | -32.07% | ||
| 5 Years | -31.45% |
CNC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
23
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | HOLD | Average Target Price | 39.647 | |
| Number of Ratings | 23 | Current Quarters Estimate | 2.172 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 2.904 | |
| Last Quarter’s Earnings | -1.24 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.031 | Next Fiscal Year Estimate | 4.152 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 17 | 17 | 20 | 17 |
| Mean Estimate | 2.17 | 0.94 | 2.90 | 4.15 |
| High Estimates | 3.82 | 1.51 | 3.66 | 4.94 |
| Low Estimate | 0.42 | 0.11 | 1.95 | 2.73 |
| Coefficient of Variance | 29.64 | 44.17 | 12.98 | 14.72 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 2 | 2 | 2 |
| HOLD | 16 | 16 | 16 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 1 | 1 | 1 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Centene Corp. - CNC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Centene Corp. - CNC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 3, 2025 | Frederick H. Eppinger Director | 359,753 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 3, 2025 | Christopher J. Coughlin Director | 12,288 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 3, 2025 | Kenneth A. Burdick Director | 338,372 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 3, 2025 | Theodore Rapp Samuels Director | 19,205 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 3, 2025 | Kenneth Yutaka Tanji Director | 5,948 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Susan Smith Chief Operating Officer | 119,923 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Susan Smith Chief Operating Officer | 59,775 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 3,478,307.25 |
| Mar 21, 2025 | Tanya M. McNally Chief People Officer | 60,458 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Tanya M. McNally Chief People Officer | 27,377 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 1,593,067.63 |
| Mar 21, 2025 | Katie N. Casso Corporate Controller & CAO | 98,412 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Katie N. Casso Corporate Controller & CAO | 70,916 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 4,126,602.04 |
| Mar 21, 2025 | Christopher A. Koster Secretary & General Counsel | 261,707 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Christopher A. Koster Secretary & General Counsel | 175,782 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 10,228,754.58 |
| Mar 21, 2025 | Sarah McGinty London Chief Executive Officer; Director | 826,045 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Sarah McGinty London Chief Executive Officer; Director | 564,832 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 32,867,574.08 |
| Mar 21, 2025 | Andrew Lynn Asher Chief Financial Officer | 668,208 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Andrew Lynn Asher Chief Financial Officer | 444,802 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 25,883,028.38 |
| Jan 6, 2025 | Wayne S. DeVeydt Director | 14,801 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Centene Corp. in the News
Centene cancels in-person investor day after UnitedHealthcare CEO killing, will hold event virtually
Managed health care company Centene announced that it canceled its in-person investor day and moved to a webinar format following the killing of UnitedHealthcare CEO Brian Thompson.
Companies thought they had a plan for fall, now they are scrapping it
The swift, startling resurgence of Covid-19 cases and hospitalizations across the U.S. is causing corporate leaders to rip up playbooks for the next few months.